Skip to main content
Robert Figlin, MD, Oncology, Los Angeles, CA, Cedars-Sinai Medical Center

RobertAlanFiglinMDFACP.(He/Him)

Oncology • Los Angeles, CA

Genitourinary Oncology, Hematologic Oncology, Thoracic Cancer

Steven Spielberg Family Chair in Hematology-Oncology Professor, Biomedical Sciences Professor, Medicine Cedars-Sinai Medical Center Professor Emeritus, Medicine and Urology, David Geffen School of Medicine, UCLA Deputy Director, the Samuel Oschin Comprehensive Cancer Institute Cedars-Sinai Medical Center Deputy Director, Cedars-Sinai Cancer, Cedars-Sinai Health System, Los Angeles, CA

Join to view full profile

Dr. Figlin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Figlin's full profile

Already have an account?

  • Office

    8700 Beverly Blvd.
    N. Tower, LL, AC1085
    Los Angeles, CA 90048
    Phone+1 310-423-1331
    Fax+1 310-248-6990
  • Is this information wrong?

Education & Training

  • UCLA David Geffen School of Medicine/UCLA Medical Center
    UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 1980 - 1982
  • Cedars-Sinai Medical Center
    Cedars-Sinai Medical CenterChief Residency, Internal Medicine, 1979 - 1980
  • Cedars-Sinai Medical Center
    Cedars-Sinai Medical CenterResidency, Internal Medicine, 1976 - 1979
  • MCP-Hahnemann College of Medicine
    MCP-Hahnemann College of MedicineClass of 1976

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 1977 - 2025
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • America's Top Doctors Castle Connolly, 2007-2014
  • Top Doctors:LA Area Castle Connolly, 2013
  • America's Top Doctors for Cancer Castle Connolly, 2006-2013
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Lectures

  • Interim data analysis of the ADAPT trial using the modified intent to treat (mITT) population re-evaluates Rocapuldencel-T for clinical benefit over standard of care. 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

  • Taking Aim at MET and KRAS in NSCLC
    Taking Aim at MET and KRAS in NSCLCOctober 31st, 2022
  • How to Choose CLL Treatments in the Frontline Setting
    How to Choose CLL Treatments in the Frontline SettingJuly 11th, 2022
  • Green Tea Extract Shows Potential as an Anti-Cancer Agent, Study Finds
    Green Tea Extract Shows Potential as an Anti-Cancer Agent, Study FindsMay 12th, 2022
  • Join now to see all

Grant Support

  • LATE Stage Lung CancerNational Cancer Institute2011
  • Cancer Center Support GrantNational Cancer Institute2007–2009
  • Oncology Research Career Development ProgramNational Cancer Institute2006–2007
  • Phase II Trial Of Recombinant Human Granulocyte MacropNational Center For Research Resources2004
  • Core--Clinical Research UnitNational Cancer Institute1994–2002
  • Trial Of Pegylated Interferon A2A In Renal Cell CancerNational Center For Research Resources2001
  • Safety And Biologic Activity Of Rhu GM-CSF And Rhu IL4 To Treat CancerNational Center For Research Resources1999–2001
  • Antigen Specific Immunotherapy In MUC 1 Positive PatientsNational Center For Research Resources1999–2001
  • Ucla/Jccc--Southwest Oncology GroupNational Cancer Institute1998–2000
  • Phase I Trial To Determine The Safety And Biologic Activity Of Rhu GM-CSFNational Center For Research Resources1998
  • Randomized Study Of Pegylated Recombinant Human Megakaryocyte GrowthNational Center For Research Resources1996–1997
  • Southwest Oncology GroupNational Cancer Institute1993–1997
  • Preliminary Efficacy Of IV ATP Treatment Of Lung CancerNational Center For Research Resources1996

Professional Memberships

Hospital Affiliations

Industry Relationships

  • Board of directors, 4D MedicalNext generation lung imaging company.2018 - Present

Dr. Robert Figlin, Dr. Robert Figlin, MD, Dr. R Figlin, Dr. Robert Alan Figlin